5-FU$DB00544$drug$Eloxatin$DB00526$true$mechanism$brand$Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks. | 
Abilify$DB01238$brand$Alcohol$DB00898$true$advise$drug$Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.| 
ACETAZOLAMIDE$DB00819$drug$SODIUM BICARBONATE$DB01390$true$effect$drug$Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.| 
Acetylcholine Chloride$DB03128$drug$Suprofen$DB00870$true$effect$drug$Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| 
acetyl-L-carnitine$DB08842$drug$alpha-Lipoic acid$DB00166$true$effect$drug$(ii) acetyl-l-carnitine elicits a significant protective effect on DEB induced toxicity, which was potentiated by  alpha-lipoic acid.| 
ACITRETIN$DB00459$drug$Glibenclamide$DB01016$true$effect$drug$Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.| 
ACTH$DB01285$group$AMPHOTERICIN B$DB00681$true$effect$drug$Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.| 
Adrenaline$DB00668$drug$Fluothane$DB01159$true$advise$brand$Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.| 
Aggrastat$DB00775$brand$Aspirin$DB00945$true$effect$brand$The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see| 
Akineton$DB00810$brand$MEPERIDINE$DB00454$true$effect$drug$Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.| 
Alcohol$DB00898$drug$Abilify$DB01238$true$advise$brand$As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY| 
Alcohol$DB00898$drug$Aspirin$DB00945$true$effect$brand$Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.| 
Alcohol$DB00898$drug$Dilaudid$DB00327$true$effect$brand$Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.| 
Alcohol$DB00898$drug$Lexapro$DB01175$true$advise$brand$Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.| 
Alcohol$DB00898$drug$Methyprylon$DB01107$true$effect$drug$Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.| 
Alcohol$DB00898$drug$Pentazocine$DB00652$true$advise$drug$Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.| 
Alcohol$DB00898$drug$Sinequan$DB01142$true$mechanism$brand$Alcohol: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage.| 
Alcohol$DB00898$drug$Vitamin B12$DB00115$true$mechanism$drug$Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.| 
Alcohol$DB00898$drug$Wellbutrin$DB01156$true$advise$brand$Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.| The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)| 
Alcohol$DB00898$drug$Wellbutrin$DB01156$true$effect$brand$Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.| The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)| 
Allegra$DB00950$brand$ALUMINUM$DB01370$true$advise$drug$ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.| 
ALLOPURINOL$DB00437$drug$AMPICILLIN$DB00415$true$effect$drug$The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.| 
ALLOPURINOL$DB00437$drug$CHLORPROPAMIDE$DB00672$true$effect$drug$The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.| Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.| 
ALLOPURINOL$DB00437$drug$CHLORPROPAMIDE$DB00672$true$mechanism$drug$The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.| Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.| 
ALLOPURINOL$DB00437$drug$Dicumarol$DB00266$true$mechanism$drug$Dicumarol: It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol.| 
ALLOPURINOL$DB00437$drug$Videx$DB00900$true$mechanism$brand$Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).| 
ALMOTRIPTAN$DB00918$drug$Ketoconazole$DB01026$true$mechanism$drug$Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.| 
ALMOTRIPTAN$DB00918$drug$Verapamil$DB00661$true$mechanism$drug$Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.| 
ALOSETRON$DB00969$drug$FLUVOXAMINE$DB00176$true$advise$drug$Concomitant administration of alosetron and fluvoxamine is contraindicated.| 
ALOSETRON$DB00969$drug$HYDRALAZINE$DB01275$true$effect$drug$Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.| 
ALOSETRON$DB00969$drug$ISONIAZID$DB00951$true$effect$drug$Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.| 
ALOSETRON$DB00969$drug$Ketoconazole$DB01026$true$advise$drug$Caution should be used when alosetron and ketoconazole are administered concomitantly.| 
ALOSETRON$DB00969$drug$VORICONAZOLE$DB00582$true$advise$drug$Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.| 
ALPRAZOLAM$DB00404$drug$AMIODARONE$DB01118$true$int$drug$Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.| 
ALPRAZOLAM$DB00404$drug$APREPITANT$DB00673$true$advise$drug$The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| 
ALPRAZOLAM$DB00404$drug$DIGOXIN$DB00390$true$mechanism$drug$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| 
ALPRAZOLAM$DB00404$drug$ERGOTAMINE$DB00696$true$int$drug$Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.| 
ALPRAZOLAM$DB00404$drug$FLUVOXAMINE$DB00176$true$advise$drug$This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.| Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.| Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| 
ALPRAZOLAM$DB00404$drug$FLUVOXAMINE$DB00176$true$effect$drug$This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.| Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.| Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| 
ALPRAZOLAM$DB00404$drug$FLUVOXAMINE$DB00176$true$mechanism$drug$This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.| Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.| Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| 
ALPRAZOLAM$DB00404$drug$ISONIAZID$DB00951$true$int$drug$Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.| 
ALPRAZOLAM$DB00404$drug$PAROXETINE$DB00715$true$int$drug$Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.| 
ALPRAZOLAM$DB00404$drug$SERTRALINE$DB01104$true$int$drug$Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.| Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.| 
ALPRAZOLAM$DB00404$drug$SERTRALINE$DB08567$true$int$drug$Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.| Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.| 
ALUMINUM HYDROXIDE$DB06723$drug$ENOXACIN$DB00467$true$mechanism$drug$Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.| 
ALUMINUM$DB01370$drug$Factive$DB01155$true$advise$brand$Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| 
ALUMINUM$DB01370$drug$Skelid$DB01133$true$mechanism$brand$The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. | 
ALUMINUM$DB01370$drug$Videx$DB00900$true$effect$brand$Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.| 
AMINOSALICYLIC ACID$DB00233$drug$DIGOXIN$DB00390$true$mechanism$drug$Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.| 
AMINOSALICYLIC ACID$DB00233$drug$Lanoxin$DB00390$true$mechanism$brand$Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.| 
AMINOSALICYLIC ACID$DB00233$drug$Vitamin B12$DB00115$true$mechanism$drug$Aminosalicylic acid may also decrease the absorption of vitamin B12, which can lead to a deficiency.| 
AMIODARONE$DB01118$drug$DIGOXIN$DB00390$true$mechanism$drug$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| Amiodarone is known to raise serum digoxin levels. | During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01). | 
AMIODARONE$DB01118$drug$Tikosyn$DB00204$true$advise$brand$Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| 
AMITRIPTYLINE$DB00321$drug$CLONIDINE$DB00575$true$effect$drug$Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.| 
AMOXICILLIN ANHYDROUS$DB01060$drug$ALLOPURINOL$DB00437$true$effect$drug$Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| 
AMPHOTERICIN B$DB00681$drug$FLUCYTOSINE$DB01099$true$effect$drug$Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.| 
AMPHOTERICIN B$DB00681$drug$HYDROCORTISONE$DB00741$true$effect$drug$In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.| 
AMPHOTERICIN B$DB00681$drug$TUBOCURARINE$DB01199$true$effect$drug$Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).| 
Amphotericin$DB00681$drug$HIVID$DB00943$true$effect$drug$Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| 
Amphotericin$DB00681$drug$ZALCITABINE$DB00943$true$mechanism$drug$Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| 
AMPICILLIN$DB00415$drug$ALLOPURINOL$DB00437$true$effect$drug$It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.| Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| 
AMPRENAVIR$DB00701$drug$RIFABUTIN$DB00615$true$effect$drug$Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. | Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. | Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. | 
AMPRENAVIR$DB00701$drug$RIFABUTIN$DB00615$true$mechanism$drug$Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. | Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. | Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. | 
AMPRENAVIR$DB00701$drug$RITONAVIR$DB00503$true$advise$drug$Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.| Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.| 
AMPRENAVIR$DB00701$drug$RITONAVIR$DB00503$true$effect$drug$Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.| Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.| 
Anafranil$DB01242$brand$DIGOXIN$DB00390$true$mechanism$drug$Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.| 
ANAGRELIDE$DB00261$drug$Aspirin$DB00945$true$effect$brand$Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.| 
ANASTROZOLE$DB01217$drug$Tamoxifen$DB00675$true$mechanism$drug$Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.| 
Antizol$DB01213$brand$Ketoconazole$DB01026$true$mechanism$drug$Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied| 
APOMORPHINE$DB00714$drug$ALOSETRON$DB00969$true$advise$drug$5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| 
APOMORPHINE$DB00714$drug$Dolasetron$DB00757$true$advise$drug$5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| 
APREPITANT$DB00673$drug$APREPITANT$DB00673$true$mechanism$drug$therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.| 
APREPITANT$DB00673$drug$DEXAMETHASONE$DB01234$true$mechanism$drug$Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.| 
APREPITANT$DB00673$drug$Ketoconazole$DB01026$true$advise$drug$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.| 
APREPITANT$DB00673$drug$Ketoconazole$DB01026$true$mechanism$drug$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.| 
APREPITANT$DB00673$drug$METHYLPREDNISOLONE$DB00959$true$mechanism$drug$Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.| 
APREPITANT$DB00673$drug$MIDAZOLAM$DB00683$true$mechanism$drug$Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.| Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.| 
APREPITANT$DB00673$drug$NEFAZODONE$DB01149$true$advise$drug$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| 
APREPITANT$DB00673$drug$NELFINAVIR$DB00220$true$advise$drug$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| 
APREPITANT$DB00673$drug$NORETHINDRONE$DB00717$true$mechanism$drug$Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;| 
APREPITANT$DB00673$drug$PAROXETINE$DB00715$true$mechanism$drug$Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.| 
APREPITANT$DB00673$drug$Rifampin$DB01045$true$mechanism$drug$Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.| therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.| 
APREPITANT$DB00673$drug$RITONAVIR$DB00503$true$advise$drug$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| 
APREPITANT$DB00673$drug$TOLBUTAMIDE$DB01124$true$mechanism$drug$Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.| 
APREPITANT$DB00673$drug$TROLEANDOMYCIN$DB01361$true$advise$drug$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| 
Arava$DB01097$brand$Rifampin$DB01045$true$advise$drug$Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.| Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.| 
Arava$DB01097$brand$Rifampin$DB01045$true$mechanism$drug$Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.| Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.| 
Aspirin$DB00945$brand$Celebrex$DB00482$true$effect$brand$However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.| 
Aspirin$DB00945$brand$Disalcid$DB01399$true$effect$brand$ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. | 
Aspirin$DB00945$brand$Fenoprofen$DB00573$true$mechanism$drug$The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.| 
Aspirin$DB00945$brand$Flurbiprofen$DB00712$true$mechanism$drug$Aspirin: Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations.| 
Aspirin$DB00945$brand$Meloxicam$DB00814$true$mechanism$drug$Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. | 
Aspirin$DB00945$brand$Methazolamide$DB00703$true$advise$drug$Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.| 
Aspirin$DB00945$brand$Mobic$DB00814$true$effect$brand$Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. | 
Aspirin$DB00945$brand$Nalfon$DB00573$true$mechanism$brand$Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.| 
Aspirin$DB00945$brand$Nicotinic Acid$DB00627$true$mechanism$drug$Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.| 
Aspirin$DB00945$brand$Nizatidine$DB00585$true$mechanism$drug$In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.| 
Aspirin$DB00945$brand$PHENYLBUTAZONE$DB00812$true$effect$drug$Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.| 
Aspirin$DB00945$brand$PROBENECID$DB01032$true$effect$drug$Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.| 
Aspirin$DB00945$brand$Retavase$DB00015$true$effect$brand$In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.| 
Aspirin$DB00945$brand$Skelid$DB01133$true$mechanism$brand$Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID. | 
Aspirin$DB00945$brand$VALDECOXIB$DB00580$true$effect$drug$Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.| 
Aspirin$DB00945$brand$Vioxx$DB00533$true$effect$brand$Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.| 
ASTEMIZOLE$DB00637$drug$Ketoconazole$DB01026$true$advise$drug$Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| 
ASTEMIZOLE$DB00637$drug$Ketoconazole$DB01026$true$mechanism$drug$Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| 
ASTEMIZOLE$DB00637$drug$Sprycel$DB01254$true$advise$brand$Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| 
Atromid-S$DB00636$brand$TOLBUTAMIDE$DB01124$true$mechanism$drug$Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.| 
Atropine$DB00572$drug$PRALIDOXIME$DB00733$true$advise$drug$The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.| When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. | When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.| 
Atropine$DB00572$drug$PRALIDOXIME$DB00733$true$effect$drug$The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.| When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. | When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.| 
Atropine$DB00572$drug$TRIPROLIDINE$DB00427$true$effect$drug$The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. | 
AURANOFIN$DB00995$drug$Cuprimine$DB00859$true$advise$brand$Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.| 
AURANOFIN$DB00995$drug$Depen$DB00859$true$advise$brand$Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.| 
Avonex$DB00060$brand$Tysabri$DB00108$true$mechanism$brand$After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.| 
AZLOCILLIN$DB01061$drug$Amikacin$DB00479$true$advise$drug$Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.| 
AZLOCILLIN$DB01061$drug$CIPROFLOXACIN$DB00537$true$advise$drug$Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.| 
AZLOCILLIN$DB01061$drug$TOBRAMYCIN$DB00684$true$advise$drug$Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.| 
BENTIROMIDE$DB00522$drug$BENZOCAINE$DB01086$true$int$drug$Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| 
BENTIROMIDE$DB00522$drug$CHLORAMPHENICOL$DB00446$true$int$drug$Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| 
BENTIROMIDE$DB00522$drug$Chloromycetin$DB00446$true$int$brand$Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| 
BENTIROMIDE$DB00522$drug$Pronestyl$DB01035$true$int$brand$Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| 
BENTIROMIDE$DB00522$drug$Tylenol$DB00316$true$int$brand$Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| 
BENZTHIAZIDE$DB00562$drug$Alcohol$DB00898$true$int$drug$Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.| 
BENZTHIAZIDE$DB00562$drug$Aleve$DB00788$true$int$brand$Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.| 
Betagan$DB01210$brand$EPINEPHRINE$DB00668$true$effect$drug$Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.| 
Betaseron$DB00068$brand$ANTIPYRINE$DB01435$true$mechanism$drug$Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.| 
BISMUTH SUBSALICYLATE$DB01294$drug$ENOXACIN$DB00467$true$mechanism$drug$Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.| 
Brevibloc$DB00187$brand$DIGOXIN$DB00390$true$advise$drug$Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| 
Brevibloc$DB00187$brand$EPINEPHRINE$DB00668$true$advise$drug$Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.| 
Brevibloc$DB00187$brand$SUCCINYLCHOLINE$DB00202$true$advise$drug$Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| 
Brevibloc$DB00187$brand$Verapamil$DB00661$true$advise$drug$Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.| 
BUPRENORPHINE$DB00921$drug$Levo-Dromoran$DB00854$true$advise$brand$Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| 
BUSPIRONE$DB00490$drug$DIGOXIN$DB00390$true$mechanism$drug$In vitro, buspirone may displace less firmly bound drugs like digoxin.| 
BUTALBITAL$DB00241$drug$Alcohol$DB00898$true$effect$drug$Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| 
BUTALBITAL$DB00241$drug$CHLORDIAZEPOXIDE$DB00475$true$effect$drug$Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| 
BUTORPHANOL$DB00611$drug$Alcohol$DB00898$true$effect$drug$Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.| 
BUTORPHANOL$DB00611$drug$Levo-Dromoran$DB00854$true$advise$brand$Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| 
Camptosar$DB00762$brand$DEXAMETHASONE$DB01234$true$effect$drug$Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect.| 
Cancidas$DB00520$brand$DEXAMETHASONE$DB01234$true$advise$drug$When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered| 
Cancidas$DB00520$brand$EFAVIRENZ$DB00625$true$advise$drug$When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered| 
CARBACHOL$DB00411$drug$Suprofen$DB00870$true$effect$drug$Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| 
Carboptic$DB00411$brand$Suprofen$DB00870$true$effect$drug$Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| 
Celebrex$DB00482$brand$Aspirin$DB00945$true$advise$brand$Aspirin: CELEBREX can be used with low dose aspirin.| 
Celebrex$DB00482$brand$FLUCONAZOLE$DB00196$true$advise$drug$CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.| 
CELECOXIB$DB00482$drug$FLUCONAZOLE$DB00196$true$int$drug$Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).| 
CELECOXIB$DB00482$drug$FLUCONAZOLE$DB00196$true$mechanism$drug$Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).| 
CEPHALEXIN ANHYDROUS$DB00567$drug$METFORMIN$DB00331$true$advise$drug$Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| 
CEPHALEXIN ANHYDROUS$DB00567$drug$METFORMIN$DB00331$true$mechanism$drug$Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| 
CEPHALEXIN ANHYDROUS$DB00567$drug$PROBENECID$DB01032$true$mechanism$drug$Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.| 
Cerezyme$DB00053$brand$Zavesca$DB00419$true$advise$brand$Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.| 
CHLOROTRIANISENE$DB00269$drug$Aspirin$DB00945$true$int$brand$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| 
CHLOROTRIANISENE$DB00269$drug$BROMOCRIPTINE$DB01200$true$int$drug$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| 
CHLOROTRIANISENE$DB00269$drug$DANTROLENE$DB01219$true$int$drug$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| 
CHLOROTRIANISENE$DB00269$drug$Somatropin$DB00052$true$int$drug$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| 
CHLOROTRIANISENE$DB00269$drug$Tamoxifen$DB00675$true$int$drug$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| 
CHLORPROMAZINE$DB00477$drug$AMITRIPTYLINE$DB00321$true$effect$drug$The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.| 
CHLORPROPAMIDE$DB00672$drug$ALLOPURINOL$DB00437$true$mechanism$drug$Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.| 
CHLORPROPAMIDE$DB00672$drug$PRAMIPEXOLE$DB00413$true$mechanism$drug$Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | 
CINACALCET$DB01012$drug$AMITRIPTYLINE$DB00321$true$mechanism$drug$Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.| 
CIPROFLOXACIN$DB00537$drug$ALUMINUM$DB01370$true$mechanism$drug$Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| 
CIPROFLOXACIN$DB00537$drug$CIPROFLOXACIN$DB00537$true$mechanism$drug$Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| 
CIPROFLOXACIN$DB00537$drug$DIDANOSINE$DB00900$true$mechanism$drug$In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.| The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.| 
CIPROFLOXACIN$DB00537$drug$Videx$DB00900$true$mechanism$brand$Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX.| 
Cisapride$DB00604$drug$Ketoconazole$DB01026$true$effect$drug$Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.| 
Cisapride$DB00604$drug$Ketoconazole$DB01026$true$mechanism$drug$Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.| 
Cisapride$DB00604$drug$Sotalol$DB00489$true$advise$drug$Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);| 
Cisapride$DB00604$drug$Sprycel$DB01254$true$advise$brand$Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| 
CLONAZEPAM$DB01068$drug$PROPANTHELINE$DB00782$true$mechanism$drug$In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.| 
CLONIDINE$DB00575$drug$Alcohol$DB00898$true$effect$drug$Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.| 
CLOTRIMAZOLE$DB00257$drug$TRIMETREXATE$DB01157$true$mechanism$drug$Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. | 
CLOZAPINE$DB00363$drug$Alcohol$DB00898$true$effect$drug$Given the primary CNS effects of Clozapine, caution is advised in using it concomitantly with other CNS-active drugs or alcohol.| 
CLOZAPINE$DB00363$drug$Atropine$DB00572$true$effect$drug$Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.| 
CLOZAPINE$DB00363$drug$Encainide$DB01228$true$advise$drug$Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.| 
CLOZAPINE$DB00363$drug$FLUVOXAMINE$DB00176$true$advise$drug$Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs, particularly with fluvoxamine.| 
CLOZAPINE$DB00363$drug$PAROXETINE$DB00715$true$mechanism$drug$However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| 
CLOZAPINE$DB00363$drug$SERTRALINE$DB01104$true$mechanism$drug$However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| 
CLOZAPINE$DB00363$drug$SERTRALINE$DB08567$true$mechanism$drug$However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| 
Copegus$DB00811$brand$DIDANOSINE$DB00900$true$advise$drug$Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.| 
Coreg$DB01136$brand$Verapamil$DB00661$true$advise$drug$As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.| 
Crixivan$DB00224$brand$ATAZANAVIR$DB01072$true$advise$drug$Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.| 
Crixivan$DB00224$brand$DELAVIRDINE$DB00705$true$advise$drug$Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.| 
Cyclophosphamide$DB00531$drug$ALLOPURINOL$DB00437$true$effect$drug$Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.| 
Cyclophosphamide$DB00531$drug$Cerubidine$DB00694$true$effect$brand$Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.| 
Cyclophosphamide$DB00531$drug$PHENOBARBITAL$DB01174$true$mechanism$drug$The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital.| 
Cyclosporin A$DB00091$drug$Etoposide$DB00773$true$mechanism$drug$High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.| 
Cytadren$DB00357$brand$DEXAMETHASONE$DB01234$true$mechanism$drug$Cytadren accelerates the metabolism of dexamethasone;| 
Cytosine arabinoside$DB00987$drug$FLUCYTOSINE$DB01099$true$effect$drug$Cytosine arabinoside, a cytostatic agent, has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.| 
d-amphetamine$DB01576$drug$PROTRIPTYLINE$DB00344$true$mechanism$drug$d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;| 
DANTROLENE$DB01219$drug$VECURONIUM$DB01339$true$effect$drug$Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.| 
DAPSONE$DB00250$drug$CLOFAZIMINE$DB00845$true$advise$drug$If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.| 
DAPSONE$DB00250$drug$Lamprene$DB00845$true$effect$brand$Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.| 
DAPSONE$DB00250$drug$PYRIMETHAMINE$DB00205$true$effect$drug$With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions| 
DECAMETHONIUM$DB01245$drug$Coly-Mycin M$DB01111$true$effect$brand$Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.| 
DELAVIRDINE$DB00705$drug$Videx$DB00900$true$advise$brand$To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| 
DELAVIRDINE$DB00705$drug$Videx$DB00900$true$mechanism$brand$To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| 
Demser$DB00765$brand$Alcohol$DB00898$true$effect$drug$Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.| 
Demser$DB00765$brand$HALOPERIDOL$DB00502$true$advise$drug$Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. | 
DEXAMETHASONE$DB01234$drug$ALBENDAZOLE$DB00518$true$mechanism$drug$Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.| 
DEXAMETHASONE$DB01234$drug$APREPITANT$DB00673$true$advise$drug$The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.| The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.| 
DEXAMETHASONE$DB01234$drug$APREPITANT$DB00673$true$mechanism$drug$The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.| The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.| 
DEXAMETHASONE$DB01234$drug$Cancidas$DB00520$true$mechanism$brand$In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.| 
DEXBROMPHENIRAMINE$DB00405$drug$Alcohol$DB00898$true$effect$drug$Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| 
DEXBROMPHENIRAMINE$DB00405$drug$Alcohol$DB00898$true$int$drug$Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| 
DEXMEDETOMIDINE$DB00633$drug$EPHEDRINE$DB01364$true$effect$drug$In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. | At the same time, the locomotor inhibitory effect of dexmedetomidine was counteracted by ephedrine. | We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.| 
Dextromethorphan$DB00514$drug$VALDECOXIB$DB00580$true$mechanism$drug$Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.| 
DEZOCINE$DB01209$drug$Levo-Dromoran$DB00854$true$advise$brand$Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| 
Diamox$DB00819$brand$PRIMIDONE$DB00794$true$advise$drug$By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.| Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.| 
Diamox$DB00819$brand$PRIMIDONE$DB00794$true$mechanism$drug$By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.| Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.| 
DIAZEPAM$DB00829$drug$FLUVOXAMINE$DB00176$true$advise$drug$Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.| 
DIAZEPAM$DB00829$drug$VALDECOXIB$DB00580$true$mechanism$drug$Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.| 
DIAZOXIDE$DB01119$drug$HYDRALAZINE$DB01275$true$effect$drug$Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.| 
DICYCLOMINE$DB00804$drug$Cisapride$DB00604$true$effect$drug$Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.| 
DIDANOSINE$DB00900$drug$Factive$DB01155$true$advise$brand$Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| 
DIDANOSINE$DB00900$drug$NORFLOXACIN$DB01059$true$advise$drug$Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.| 
Diflucan$DB00196$brand$GLIPIZIDE$DB01067$true$mechanism$drug$DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. | 
Diflucan$DB00196$brand$Rifampin$DB01045$true$advise$drug$Depending on clinical circumstances, consideration should be given to increasing the dose of DIFLUCAN when it is administered with rifampin. | 
Diflucan$DB00196$brand$TOLBUTAMIDE$DB01124$true$mechanism$drug$DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. | 
Diflunisal$DB00861$drug$Aspirin$DB00945$true$mechanism$brand$Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.| 
Diflunisal$DB00861$drug$Indocin$DB00328$true$advise$brand$Therefore, diflunisal and INDOCIN should not be used concomitantly.| 
Diflunisal$DB00861$drug$NAPROXEN$DB00788$true$mechanism$drug$Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.| 
DIGOXIN$DB00390$drug$Adenocard$DB00640$true$effect$brand$Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.| 
DIGOXIN$DB00390$drug$AMINOSALICYLIC ACID$DB00233$true$advise$drug$In the case that you are taking digoxin while taking aminosalicylic acid, higher doses of digoxin may be needed.| 
DIGOXIN$DB00390$drug$AMIODARONE$DB01118$true$mechanism$drug$These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.| 
DIGOXIN$DB00390$drug$Brevibloc$DB00187$true$mechanism$brand$When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.| 
DIGOXIN$DB00390$drug$CONIVAPTAN$DB00872$true$mechanism$drug$Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.| 
DIGOXIN$DB00390$drug$Coreg$DB01136$true$advise$brand$Both digoxin and COREG slow AV conduction.| Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.| 
DIGOXIN$DB00390$drug$Coreg$DB01136$true$effect$brand$Both digoxin and COREG slow AV conduction.| Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.| 
DIGOXIN$DB00390$drug$DIGOXIN$DB00390$true$mechanism$drug$Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.| 
DIGOXIN$DB00390$drug$DOFETILIDE$DB00204$true$effect$drug$In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.| 
DIGOXIN$DB00390$drug$Flolan$DB01240$true$mechanism$brand$However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.| In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.| 
DIGOXIN$DB00390$drug$Ketoconazole$DB01026$true$advise$drug$It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.| 
DIGOXIN$DB00390$drug$METOCLOPRAMIDE$DB01233$true$mechanism$drug$Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). | 
DIGOXIN$DB00390$drug$SITAGLIPTIN$DB01261$true$mechanism$drug$Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. | 
DIGOXIN$DB00390$drug$SULFASALAZINE$DB00795$true$mechanism$drug$Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. | 
DIGOXIN$DB00390$drug$Vaprisol$DB00872$true$mechanism$brand$Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.| 
DIHYDROERGOTAMINE$DB00320$drug$Axert$DB00918$true$advise$brand$Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.| 
DIHYDROERGOTAMINE$DB00320$drug$Frova$DB00998$true$advise$brand$Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).| 
DIHYDROERGOTAMINE$DB00320$drug$NARATRIPTAN$DB00952$true$advise$drug$Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.| 
DIHYDROERGOTAMINE$DB00320$drug$ProAmatine$DB00211$true$effect$brand$The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | 
DIHYDROERGOTAMINE$DB00320$drug$Sprycel$DB01254$true$advise$brand$Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| 
DIHYDROERGOTAMINE$DB00320$drug$SUMATRIPTAN$DB00669$true$advise$drug$Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | 
DIPHENIDOL$DB01231$drug$APOMORPHINE$DB00714$true$effect$drug$apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.| 
DIPHENOXYLATE$DB01081$drug$DIGOXIN$DB00390$true$mechanism$drug$Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.| 
Diprivan$DB00818$brand$Fentanyl$DB00813$true$effect$drug$The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) | 
Diprivan$DB00818$brand$MEPERIDINE$DB00454$true$effect$drug$The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) | 
Dipyrone$DB04817$drug$Aspirin$DB00945$true$effect$drug$Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| 
Dobutamine$DB00841$drug$SODIUM BICARBONATE$DB01390$true$int$drug$norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. | 
Dolasetron$DB00757$drug$Rifampin$DB01045$true$mechanism$drug$Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.| 
Dostinex$DB00248$brand$METOCLOPRAMIDE$DB01233$true$advise$drug$DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.| 
DULOXETINE$DB00476$drug$AMITRIPTYLINE$DB00321$true$advise$drug$Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| 
DULOXETINE$DB00476$drug$FLUVOXAMINE$DB00176$true$mechanism$drug$Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.| 
DULOXETINE$DB00476$drug$IMIPRAMINE$DB00458$true$advise$drug$Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| 
DULOXETINE$DB00476$drug$NORTRIPTYLINE$DB00540$true$advise$drug$Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| 
Duragesic$DB00813$brand$Alcohol$DB00898$true$effect$drug$Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.| 
EFAVIRENZ$DB00625$drug$Cancidas$DB00520$true$mechanism$brand$In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.| 
Enablex$DB00496$brand$Ketoconazole$DB01026$true$advise$drug$The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| 
Enablex$DB00496$brand$NELFINAVIR$DB00220$true$advise$drug$The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| 
Enablex$DB00496$brand$RITONAVIR$DB00503$true$advise$drug$The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| 
ENOXACIN$DB00467$drug$BISMUTH SUBSALICYLATE$DB01294$true$advise$drug$Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.| 
ENOXACIN$DB00467$drug$DIGOXIN$DB00390$true$effect$drug$If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.| Digoxin: Enoxacin may raise serum digoxin levels in some individuals.| 
ENOXACIN$DB00467$drug$DIGOXIN$DB00390$true$mechanism$drug$If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.| Digoxin: Enoxacin may raise serum digoxin levels in some individuals.| 
ENOXIMONE$DB04880$drug$ANAGRELIDE$DB00261$true$effect$drug$The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| 
EPA$DB00159$drug$Aspirin$DB00945$true$int$brand$Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).| 
EPHEDRINE$DB01364$drug$DEXMEDETOMIDINE$DB00633$true$effect$drug$Ephedrine enhances the antinociceptive effect of dexmedetomidine in mice.&#x0D;|
EPHEDRINE$DB01364$drug$LEVOMEPROMAZINE$DB01403$true$effect$drug$Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. | 
EPHEDRINE$DB01364$drug$ProAmatine$DB00211$true$effect$brand$The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | 
EPINEPHRINE$DB00668$drug$GUANETHIDINE$DB01170$true$effect$drug$Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.| 
EPINEPHRINE$DB00668$drug$Isoproterenol$DB01064$true$advise$drug$Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.| 
Ergamisol$DB00848$brand$Alcohol$DB00898$true$effect$drug$ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.| 
Ergomar$DB00696$brand$Triacetyloleandomycin$DB01361$true$mechanism$drug$The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.| 
ERGOTAMINE$DB00696$drug$Axert$DB00918$true$advise$brand$Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.| 
ERGOTAMINE$DB00696$drug$Frova$DB00998$true$advise$brand$Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).| 
ERGOTAMINE$DB00696$drug$NARATRIPTAN$DB00952$true$advise$drug$Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.| 
ERGOTAMINE$DB00696$drug$Sprycel$DB01254$true$advise$brand$Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| 
ERGOTAMINE$DB00696$drug$SUMATRIPTAN$DB00669$true$advise$drug$Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | 
ERTAPENEM$DB00303$drug$PROBENECID$DB01032$true$mechanism$drug$Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.| 
ESCITALOPRAM$DB01175$drug$Celexa$DB00215$true$advise$brand$Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.| 
ESTAZOLAM$DB01215$drug$ESTAZOLAM$DB01215$true$mechanism$drug$While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| 
ESTAZOLAM$DB01215$drug$Ketoconazole$DB01026$true$advise$drug$Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.| 
ESTAZOLAM$DB01215$drug$Rifampin$DB01045$true$mechanism$drug$While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| 
Estradiol$DB00783$drug$Noradrenaline$DB00368$true$effect$drug$Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively). | Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). | 
ESZOPICLONE$DB00402$drug$Ketoconazole$DB01026$true$mechanism$drug$The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.| 
ESZOPICLONE$DB00402$drug$OLANZAPINE$DB00334$true$effect$drug$Olanzapine: Coadministration of eszopiclone 3 mg and olanzapine 10 mg produced a decrease in DSST scores.| 
ETHAMBUTOL$DB00330$drug$ALUMINUM HYDROXIDE$DB06723$true$advise$drug$The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.| It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.| 
ETHAMBUTOL$DB00330$drug$ALUMINUM HYDROXIDE$DB06723$true$mechanism$drug$The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.| It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.| 
ETHIONAMIDE$DB00609$drug$CYCLOSERINE$DB00260$true$effect$drug$In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.| 
ETHOXZOLAMIDE$DB00311$drug$AMPHOTERICIN B$DB00681$true$effect$drug$Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.| 
Etodolac$DB00749$drug$PHENYLBUTAZONE$DB00812$true$advise$drug$Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.| 
ETONOGESTREL$DB00294$drug$Agenerase$DB00701$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$AMPICILLIN$DB00415$true$int$drug$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Atromid-S$DB00636$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$CLOFIBRATE$DB00636$true$int$drug$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Crixivan$DB00224$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Dilantin$DB00252$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Felbatol$DB00949$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Fortovase$DB01232$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Gris-PEG$DB00400$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Invirase$DB01232$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Kadian$DB00295$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Lipitor$DB01076$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$MS Contin$DB00295$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Neoral $DB00091$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Nizoral$DB01026$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Norvir$DB00503$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$PHENOBARBITAL$DB01174$true$int$drug$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$PHENYLBUTAZONE$DB00812$true$int$drug$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Prelone$DB00860$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Rifadin$DB01045$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Rifampin$DB01045$true$int$drug$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Sandimmune $DB00091$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Sporanox$DB01167$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$TEGretol$DB00564$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Theo-Dur$DB00277$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Topamax$DB00273$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Trileptal$DB00776$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Tylenol$DB00316$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Viracept$DB00220$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
Evista$DB00481$brand$CLOFIBRATE$DB00636$true$advise$drug$Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | 
Evista$DB00481$brand$DIAZEPAM$DB00829$true$advise$drug$Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | 
Evista$DB00481$brand$DIAZOXIDE$DB01119$true$advise$drug$Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | 
Evista$DB00481$brand$NAPROXEN$DB00788$true$advise$drug$Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | 
Exjade$DB01609$brand$ALUMINUM$DB01370$true$advise$drug$Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.| 
Factive$DB01155$brand$PROBENECID$DB01032$true$mechanism$drug$Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.| 
FAMOTIDINE$DB00927$drug$Cefditoren Pivoxil$DB01066$true$mechanism$drug$H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.| 
Felbatol$DB00949$brand$Valproate$DB00313$true$mechanism$drug$Valproate: Felbatol  causes an increase in steady-state valproate concentrations.| 
Feldene$DB00554$brand$Aspirin$DB00945$true$mechanism$brand$Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. | 
Felodipine$DB01023$drug$PHENOBARBITAL$DB01174$true$mechanism$drug$Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.| 
Femara$DB01006$brand$Tamoxifen$DB00675$true$mechanism$drug$(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.| 
FENOFIBRATE$DB01039$drug$EZETIMIBE$DB00973$true$mechanism$drug$Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. | 
Fenoprofen$DB00573$drug$Aspirin$DB00945$true$mechanism$brand$Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.| 
Fentanyl$DB00813$drug$Alcohol$DB00898$true$effect$drug$Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.| 
Fentanyl$DB00813$drug$Ketoconazole$DB01026$true$mechanism$drug$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| 
Fentanyl$DB00813$drug$NELFINAVIR$DB00220$true$mechanism$drug$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| 
Fentanyl$DB00813$drug$RITONAVIR$DB00503$true$mechanism$drug$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| 
Fentanyl$DB00813$drug$Sprycel$DB01254$true$advise$brand$Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| 
Fentanyl$DB00813$drug$TROLEANDOMYCIN$DB01361$true$mechanism$drug$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| 
Flexeril$DB00924$brand$Alcohol$DB00898$true$effect$drug$FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.| 
FLUCONAZOLE$DB00196$drug$ASTEMIZOLE$DB00637$true$mechanism$drug$Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. | 
FLUCONAZOLE$DB00196$drug$CELECOXIB$DB00482$true$mechanism$drug$Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.| 
FLUCONAZOLE$DB00196$drug$Cisapride$DB00604$true$advise$drug$The combined use of fluconazole with cisapride is contraindicated. | Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. | A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.| 
FLUCONAZOLE$DB00196$drug$Cisapride$DB00604$true$effect$drug$The combined use of fluconazole with cisapride is contraindicated. | Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. | A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.| 
FLUCONAZOLE$DB00196$drug$Cisapride$DB00604$true$mechanism$drug$The combined use of fluconazole with cisapride is contraindicated. | Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. | A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.| 
FLUCONAZOLE$DB00196$drug$GLIPIZIDE$DB01067$true$int$drug$The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.| 
FLUCONAZOLE$DB00196$drug$LEVONORGESTREL$DB00367$true$mechanism$drug$While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. | Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; | 
FLUCONAZOLE$DB00196$drug$MIDAZOLAM$DB00683$true$mechanism$drug$Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | 
FLUCONAZOLE$DB00196$drug$RIFABUTIN$DB00615$true$effect$drug$Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered. | 
Fludara$DB01073$brand$PENTOSTATIN$DB00552$true$advise$drug$The use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity.| 
Fluothane$DB01159$brand$TUBOCURARINE$DB01199$true$effect$drug$FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.| 
FLUPHENAZINE$DB00623$drug$CLONIDINE$DB00575$true$effect$drug$There is one reported case of a patient with acute delirium associated with the simultaneous use of fluphenazine and oral clonidine.| 
Flurbiprofen$DB00712$drug$Aspirin$DB00945$true$advise$brand$Concurrent use of flurbiprofen and aspirin is therefore not recommended.| 
FLUVOXAMINE$DB00176$drug$ALOSETRON$DB00969$true$mechanism$drug$Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.| 
FLUVOXAMINE$DB00176$drug$ALPRAZOLAM$DB00404$true$int$drug$Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.| 
FLUVOXAMINE$DB00176$drug$ANAGRELIDE$DB00261$true$mechanism$drug$It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide.| 
FLUVOXAMINE$DB00176$drug$ASTEMIZOLE$DB00637$true$advise$drug$Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| 
FLUVOXAMINE$DB00176$drug$Cisapride$DB00604$true$advise$drug$Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| 
FLUVOXAMINE$DB00176$drug$DIAZEPAM$DB00829$true$advise$drug$Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.| Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.| Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.| 
FLUVOXAMINE$DB00176$drug$DIAZEPAM$DB00829$true$mechanism$drug$Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.| Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.| Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.| 
FLUVOXAMINE$DB00176$drug$Ropivacaine$DB00296$true$int$drug$Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. | 
FLUVOXAMINE$DB00176$drug$SUMATRIPTAN$DB00669$true$effect$drug$Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | 
FLUVOXAMINE$DB00176$drug$TERBINAFINE$DB00857$true$advise$drug$Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| 
FLUVOXAMINE$DB00176$drug$TOLBUTAMIDE$DB01124$true$mechanism$drug$Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.| RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. | 
FLUVOXAMINE$DB00176$drug$Xanax$DB00404$true$advise$brand$Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).| 
FOSCARNET$DB00529$drug$HIVID$DB00943$true$effect$drug$Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| 
FOSCARNET$DB00529$drug$ZALCITABINE$DB00943$true$mechanism$drug$Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| 
Foscavir$DB00529$brand$AMPHOTERICIN B$DB00681$true$advise$drug$Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| 
Foscavir$DB00529$brand$PENTAMIDINE$DB00738$true$advise$drug$Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;| A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.| 
Foscavir$DB00529$brand$PENTAMIDINE$DB00738$true$effect$drug$Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;| A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.| 
Foscavir$DB00529$brand$PENTAMIDINE$DB00738$true$int$drug$Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;| A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.| 
GEMFIBROZIL$DB01241$drug$BEXAROTENE$DB00307$true$mechanism$drug$On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.| 
GEMFIBROZIL$DB01241$drug$Targretin$DB00307$true$advise$brand$Concomitant administration of gemfibrozil with Targretin capsules is not recommended.| 
Gleevec$DB00619$brand$Ketoconazole$DB01026$true$advise$drug$Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).| 
Gleevec$DB00619$brand$Ketoconazole$DB01026$true$mechanism$drug$Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).| 
Gleevec$DB00619$brand$PIMOZIDE$DB01100$true$advise$drug$Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).| 
GLIPIZIDE$DB01067$drug$FLUCONAZOLE$DB00196$true$mechanism$drug$The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).| 
GRISEOFULVIN$DB00400$drug$Levulan Kerastick$DB00855$true$effect$brand$It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.| 
GUANETHIDINE$DB01170$drug$MINOXIDIL$DB00350$true$advise$drug$If at all possible guanethidine should be discontinued well before minoxidil is begun. | 
GUANETHIDINE$DB01170$drug$Zebeta$DB00612$true$effect$brand$Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.| 
GUANFACINE$DB01018$drug$PHENOBARBITAL$DB01174$true$mechanism$drug$The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.| 
Haldol$DB00502$brand$Alcohol$DB00898$true$effect$drug$As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.| 
HALOPERIDOL$DB00502$drug$PCP$DB03575$true$effect$drug_n$Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. | 
HALOPERIDOL$DB00502$drug$Rifampin$DB01045$true$mechanism$drug$In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.| 
HCTZ$DB00999$drug$DOFETILIDE$DB00204$true$mechanism$drug$In patients receiving HCTZ alone, dofetilide AUC increased by 27% and Cmax by 21%.| 
Herceptin$DB00072$brand$LAPATINIB$DB01259$true$effect$drug$Furthermore, we present a case report in which a second Herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. | 
HIVID$DB00943$drug$DIDANOSINE$DB00900$true$advise$drug$Concomitant use of HIVID with didanosine is not recommended.| 
Imiglucerase$DB06720$drug$Zavesca$DB00419$true$advise$brand$Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.| 
IMIPRAMINE$DB00458$drug$ALPRAZOLAM$DB00404$true$mechanism$drug$The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.| 
INAMRINONE$DB01427$drug$ANAGRELIDE$DB00261$true$effect$drug$The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| 
Indocin$DB00328$brand$Diflunisal$DB00861$true$effect$drug$In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.| 
Indocin$DB00328$brand$DIGOXIN$DB00390$true$advise$drug$Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.| INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.| 
Indocin$DB00328$brand$DIGOXIN$DB00390$true$mechanism$drug$Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.| INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.| 
Indocin$DB00328$brand$PROBENECID$DB01032$true$mechanism$drug$When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.| 
Indocin$DB00328$brand$TRIAMTERENE$DB00384$true$advise$drug$INDOCIN and triamterene should not be administered together.| 
INH$DB00951$drug$Ketoconazole$DB01026$true$mechanism$drug$INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.| 
INSPRA$DB00700$brand$Enalapril$DB00584$true$effect$drug$In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.| 
INSPRA$DB00700$brand$Ketoconazole$DB01026$true$mechanism$drug$A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.| 
Invega$DB01267$brand$Alcohol$DB00898$true$advise$drug$Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. | 
Invirase$DB01232$brand$RITONAVIR$DB00503$true$advise$drug$Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.| 
Iopidine$DB00964$brand$Alcohol$DB00898$true$advise$drug$Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.| 
Irbesartan$DB01029$drug$ALISKIREN$DB01258$true$mechanism$drug$Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.| 
ISOCARBOXAZID$DB01247$drug$Antabuse$DB00822$true$advise$brand$Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).| 
Isoflurane$DB00753$drug$Nimbex$DB00565$true$advise$brand$Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.| In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.| 
Isoflurane$DB00753$drug$Nimbex$DB00565$true$effect$brand$Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.| In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.| 
Isoflurane$DB00753$drug$Nuromax$DB01135$true$mechanism$brand$Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.| 
ISONIAZID$DB00951$drug$Ketoconazole$DB01026$true$mechanism$drug$INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.| 
ISONIAZID$DB00951$drug$Valproate$DB00313$true$advise$drug$Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.| 
Isopto Carbachol$DB00411$brand$Suprofen$DB00870$true$effect$drug$Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| 
Ketoconazole$DB01026$drug$ALISKIREN$DB01258$true$mechanism$drug$Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.| 
Ketoconazole$DB01026$drug$ALOSETRON$DB00969$true$mechanism$drug$Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.| 
Ketoconazole$DB01026$drug$ARIPIPRAZOLE$DB01238$true$advise$drug$Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.| Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.| 
Ketoconazole$DB01026$drug$ARIPIPRAZOLE$DB01238$true$mechanism$drug$Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.| Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.| 
Ketoconazole$DB01026$drug$ASTEMIZOLE$DB00637$true$effect$drug$Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.| Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.| 
Ketoconazole$DB01026$drug$ASTEMIZOLE$DB00637$true$mechanism$drug$Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.| Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.| 
Ketoconazole$DB01026$drug$BEXAROTENE$DB00307$true$mechanism$drug$On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.| 
Ketoconazole$DB01026$drug$CINACALCET$DB01012$true$mechanism$drug$Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.| 
Ketoconazole$DB01026$drug$Cisapride$DB00604$true$advise$drug$Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.| Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.| Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.| Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.| 
Ketoconazole$DB01026$drug$Cisapride$DB00604$true$effect$drug$Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.| Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.| Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.| Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.| 
Ketoconazole$DB01026$drug$Cisapride$DB00604$true$mechanism$drug$Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.| Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.| Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.| Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.| 
Ketoconazole$DB01026$drug$COUMARIN$DB04665$true$effect$group$When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.| 
Ketoconazole$DB01026$drug$ISONIAZID$DB00951$true$int$drug$Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.| 
Ketoconazole$DB01026$drug$LAPATINIB$DB01259$true$mechanism$drug$Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.| 
Ketoconazole$DB01026$drug$LORATADINE$DB00455$true$mechanism$drug$After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.| 
Ketoconazole$DB01026$drug$METHYLPREDNISOLONE$DB00959$true$mechanism$drug$Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. | Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.| 
Ketoconazole$DB01026$drug$MIDAZOLAM$DB00683$true$mechanism$drug$Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | 
Ketoconazole$DB01026$drug$MIFEPRISTONE$DB00834$true$mechanism$drug$Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). | 
Ketoconazole$DB01026$drug$Mometasone Furoate$DB00764$true$mechanism$drug$However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing.| 
Ketoconazole$DB01026$drug$PARICALCITOL$DB00910$true$mechanism$drug$A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | 
Ketoconazole$DB01026$drug$Ropivacaine$DB00296$true$mechanism$drug$Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.| 
Ketoconazole$DB01026$drug$Tikosyn$DB00204$true$mechanism$brand$Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.| 
Ketoconazole$DB01026$drug$TOLTERODINE$DB01036$true$mechanism$drug$CYP3A4 Inhibitors: Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions). | 
Ketoconazole$DB01026$drug$TRIMETREXATE$DB01157$true$mechanism$drug$Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. | 
Ketoconazole$DB01026$drug$VARDENAFIL$DB00862$true$mechanism$drug$Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.| 
Ketoconazole$DB01026$drug$Videx$DB00900$true$advise$brand$Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.| 
Ketoconazole$DB01026$drug$Viracept$DB00220$true$mechanism$brand$Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.| 
Ketoconazole$DB01026$drug$ZALEPLON$DB00962$true$mechanism$drug$Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.| 
Lamivudine$DB00709$drug$ZALCITABINE$DB00943$true$advise$drug$Therefore, use of lamivudine in combination with zalcitabine is not recommended| Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.| Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.| 
Lamivudine$DB00709$drug$ZALCITABINE$DB00943$true$effect$drug$Therefore, use of lamivudine in combination with zalcitabine is not recommended| Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.| Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.| 
Lansoprazole$DB00448$drug$AMPICILLIN$DB00415$true$mechanism$drug$therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| 
Lansoprazole$DB00448$drug$DIGOXIN$DB00390$true$mechanism$drug$therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| 
Lansoprazole$DB00448$drug$Ketoconazole$DB01026$true$mechanism$drug$therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| 
LAPATINIB$DB01259$drug$Herceptin$DB00072$true$effect$brand$In an in vitro assay, lapatinib induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC. | Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.| Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.&#x0D;
| 
Levo-Dromoran$DB00854$brand$Alcohol$DB00898$true$effect$drug$Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.| 
LEVOTHYROXINE$DB00451$drug$Estrogens$DB00286$true$mechanism$group$In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.| 
Levsin$DB00424$brand$HALOPERIDOL$DB00502$true$effect$drug$Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.| 
Lodine$DB00749$brand$Aspirin$DB00945$true$advise$brand$however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.| Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.| 
Lodine$DB00749$brand$Aspirin$DB00945$true$mechanism$brand$however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.| Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.| 
Lodine$DB00749$brand$DIGOXIN$DB00390$true$mechanism$drug$Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.| 
LOPINAVIR$DB01601$drug$Sustiva$DB00625$true$advise$brand$A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.| 
Mazindol$DB00579$drug$GUANETHIDINE$DB01170$true$effect$drug$Mazindol may reduce the effects of guanethidine (Ismelin). | 
Mazindol$DB00579$drug$Ismelin$DB01170$true$effect$brand$Mazindol may reduce the effects of guanethidine (Ismelin). | 
Mazindol$DB00579$drug$ISOCARBOXAZID$DB01247$true$advise$drug$You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | 
Mazindol$DB00579$drug$Marplan$DB01247$true$advise$brand$You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | 
Mazindol$DB00579$drug$Nardil$DB00780$true$advise$brand$You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | 
Mazindol$DB00579$drug$Parnate$DB00752$true$advise$brand$You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | 
Mazindol$DB00579$drug$PHENELZINE$DB00780$true$advise$drug$You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | 
Mazindol$DB00579$drug$Tranylcypromine$DB00752$true$advise$drug$You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | 
Melatonin$DB01065$drug$Aspirin$DB00945$true$int$brand$Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).| 
Melatonin$DB01065$drug$FLUVOXAMINE$DB00176$true$int$drug$Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).| 
Meloxicam$DB00814$drug$Aspirin$DB00945$true$advise$brand$however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. | 
MEPERIDINE$DB00454$drug$Alcohol$DB00898$true$advise$drug$Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). | 
Meropenem$DB00760$drug$VALPROIC ACID$DB00313$true$mechanism$drug$There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).| 
METFORMIN$DB00331$drug$DOFETILIDE$DB00204$true$advise$drug$In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| 
METHAMPHETAMINE$DB01577$drug$PARGYLINE$DB01626$true$effect$drug$Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment. | 
METHYLPREDNISOLONE$DB00959$drug$APREPITANT$DB00673$true$advise$drug$The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.| 
METHYLPREDNISOLONE$DB00959$drug$Aspirin$DB00945$true$mechanism$brand$Methylprednisolone may increase the clearance of chronic high dose aspirin. | 
METOCLOPRAMIDE$DB01233$drug$Alcohol$DB00898$true$effect$drug$Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. | 
METOCLOPRAMIDE$DB01233$drug$Apokyn$DB00714$true$effect$brand$Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.| 
METOCLOPRAMIDE$DB01233$drug$DIGOXIN$DB00390$true$mechanism$drug$Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.| 
METOCLOPRAMIDE$DB01233$drug$Permax$DB01186$true$advise$brand$Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); | 
METOCLOPRAMIDE$DB01233$group$Mirapex$DB00413$true$effect$brand$Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. | 
METRONIDAZOLE$DB00916$drug$COUMARIN$DB04665$true$effect$group$Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. | 
MIDAZOLAM$DB00683$drug$APREPITANT$DB00673$true$advise$drug$The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| 
MIDAZOLAM$DB00683$drug$FLUCONAZOLE$DB00196$true$effect$drug$This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. | Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. | 
MIDAZOLAM$DB00683$drug$FLUCONAZOLE$DB00196$true$mechanism$drug$This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. | Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. | 
MIDAZOLAM$DB00683$drug$FLUVOXAMINE$DB00176$true$mechanism$drug$Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| 
MILRINONE$DB00235$drug$ANAGRELIDE$DB00261$true$effect$drug$The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| 
MINOXIDIL$DB00350$drug$GUANETHIDINE$DB01170$true$effect$drug$Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. | 
Mivacron$DB01226$brand$Colistin$DB00803$true$int$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | 
MOCLOBEMIDE$DB01171$drug$ALMOTRIPTAN$DB00918$true$mechanism$drug$Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.| 
Monurol$DB00828$brand$METOCLOPRAMIDE$DB01233$true$mechanism$drug$Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.| 
Myfortic$DB01024$brand$ALUMINUM$DB01370$true$mechanism$drug$Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. | 
Nabilone$DB00486$drug$Alcohol$DB00898$true$advise$drug$Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).| Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| 
Nabilone$DB00486$drug$Alcohol$DB00898$true$effect$drug$Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).| Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| 
Nabilone$DB00486$drug$DIAZEPAM$DB00829$true$effect$drug$Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| 
NALBUPHINE$DB00844$drug$Levo-Dromoran$DB00854$true$advise$brand$Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| 
NALIDIXIC ACID$DB00779$drug$MELPHALAN$DB01042$true$effect$drug$DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  | 
NALTREXONE$DB00704$drug$ACAMPROSATE$DB00659$true$mechanism$drug$Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.| 
NAPROXEN$DB00788$drug$Aspirin$DB00945$true$advise$brand$Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.| 
NEFAZODONE$DB01149$drug$Cisapride$DB00604$true$mechanism$drug$Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| 
NELFINAVIR$DB00220$drug$AMPRENAVIR$DB00701$true$mechanism$drug$Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.| 
NELFINAVIR$DB00220$drug$DIDANOSINE$DB00900$true$advise$drug$therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine.| 
NELFINAVIR$DB00220$drug$MIDAZOLAM$DB00683$true$mechanism$drug$Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. | 
Nimbex$DB00565$brand$Colistin$DB00803$true$effect$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| 
Nimbex$DB00565$brand$SUCCINYLCHOLINE$DB00202$true$effect$drug$Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced  95% neuromuscular block.| The time to onset of maximum block following NIMBEX is approximately 2 minutes faster with prior administration of succinylcholine.| 
NITROGLYCERIN$DB00727$drug$INOmax$DB00435$true$effect$brand$Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.| 
Nizoral$DB01026$brand$MIDAZOLAM$DB00683$true$mechanism$drug$Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.| 
Nizoral$DB01026$brand$TRIAZOLAM$DB00897$true$mechanism$drug$Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.| 
NORETHINDRONE$DB00717$drug$GABAPENTIN$DB00996$true$mechanism$drug$The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;| 
NORFLOXACIN$DB01059$drug$Tikosyn$DB00204$true$advise$brand$Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| 
Nuromax$DB01135$brand$Colistin$DB00803$true$effect$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| 
OUABAIN$DB01092$drug$DROPERIDOL$DB00450$true$effect$drug$Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.| 
OUABAIN$DB01092$drug$PHENTOLAMINE$DB00692$true$effect$drug$When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished. | 
Oxyphenbutazone$DB03585$drug$Aspirin$DB00945$true$effect$drug$Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| 
para-aminosalicylic acid$DB00233$drug$Vitamin B12$DB00115$true$mechanism$drug$Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.| 
PARICALCITOL$DB00910$drug$ATAZANAVIR$DB01072$true$advise$drug$A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | 
PARICALCITOL$DB00910$drug$Ketoconazole$DB01026$true$advise$drug$A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | 
PARICALCITOL$DB00910$drug$NEFAZODONE$DB01149$true$advise$drug$A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | 
PARICALCITOL$DB00910$drug$NELFINAVIR$DB00220$true$advise$drug$A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | 
PARICALCITOL$DB00910$drug$RITONAVIR$DB00503$true$advise$drug$A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | 
PARICALCITOL$DB00910$drug$VORICONAZOLE$DB00582$true$advise$drug$A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | 
PAROXETINE$DB00715$drug$ARIPIPRAZOLE$DB01238$true$mechanism$drug$Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| 
PAROXETINE$DB00715$drug$ATOMOXETINE$DB00289$true$mechanism$drug$In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.| 
PAROXETINE$DB00715$drug$CLOZAPINE$DB00363$true$mechanism$drug$Paroxetine produced only minor changes in the levels of clozapine and its metabolites.| 
PAROXETINE$DB00715$drug$DULOXETINE$DB00476$true$mechanism$drug$Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.| 
PAROXETINE$DB00715$drug$SUMATRIPTAN$DB00669$true$effect$drug$Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | 
Peganone$DB00754$brand$PHENACEMIDE$DB01121$true$advise$drug$Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.| 
Peganone$DB00754$brand$Phenurone$DB01121$true$advise$brand$Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.| 
PENTAMIDINE$DB00738$drug$HIVID$DB00943$true$advise$drug$Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.| If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.| 
PENTAMIDINE$DB00738$drug$HIVID$DB00943$true$effect$drug$Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.| If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.| 
Pentazocine$DB00652$drug$Levo-Dromoran$DB00854$true$advise$brand$Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| 
Pentazocine$DB00652$drug$TRIPELENNAMINE$DB00792$true$effect$drug$Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination. | 
PHENOBARBITAL$DB01174$drug$Aspirin$DB00945$true$mechanism$brand$Phenobarbital: Decreases aspirin effectiveness by enzyme induction.| 
PHENOBARBITAL$DB01174$drug$BEXAROTENE$DB00307$true$mechanism$drug$Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| 
PHENOBARBITAL$DB01174$drug$CALCITRIOL$DB00136$true$mechanism$drug$Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.| 
PHENOBARBITAL$DB01174$drug$CLONAZEPAM$DB01068$true$mechanism$drug$Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.| 
PHENOBARBITAL$DB01174$drug$EFAVIRENZ$DB00625$true$mechanism$drug$Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.| 
PHENOBARBITAL$DB01174$drug$EXEMESTANE$DB00990$true$mechanism$drug$Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.| 
PHENOBARBITAL$DB01174$drug$Fenoprofen$DB00573$true$mechanism$drug$Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.| 
PHENOBARBITAL$DB01174$drug$METHYLPREDNISOLONE$DB00959$true$advise$drug$Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | 
PHENOBARBITAL$DB01174$drug$METHYLPREDNISOLONE$DB00959$true$mechanism$drug$Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | 
PHENOBARBITAL$DB01174$drug$Mexitil$DB00379$true$mechanism$brand$When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. | 
PHENOBARBITAL$DB01174$drug$MIFEPRISTONE$DB00834$true$mechanism$drug$John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). | 
PHENOBARBITAL$DB01174$drug$MONTELUKAST$DB00471$true$advise$drug$It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.| 
PHENOBARBITAL$DB01174$drug$Nalfon$DB00573$true$advise$brand$When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.| 
PHENOBARBITAL$DB01174$drug$Trileptal$DB00776$true$mechanism$brand$The increase of phenobarbital level, however, is small (15%) when given with Trileptal.| 
PHENYLBUTAZONE$DB00812$drug$Aspirin$DB00945$true$effect$drug$Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| 
PHENYLBUTAZONE$DB00812$drug$Etodolac$DB00749$true$mechanism$drug$Phenylbutazone: Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.| 
PHENYLEPHRINE$DB00388$drug$ProAmatine$DB00211$true$effect$brand$The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | 
Phospholine Iodide$DB01057$drug$SUCCINYLCHOLINE$DB00202$true$effect$drug$Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.| 
PHYSOSTIGMINE$DB00981$drug$Alcohol$DB00898$true$effect$drug$Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. | 
PIMOZIDE$DB01100$drug$Sprycel$DB01254$true$advise$brand$Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| 
PIPERACILLIN ANHYDROUS$DB00319$drug$VECURONIUM$DB01339$true$effect$drug$In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.| Vecuronium: When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.| 
Pletal$DB01166$brand$Ketoconazole$DB01026$true$advise$drug$Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.| 
Ponstel$DB00784$brand$Aspirin$DB00945$true$advise$brand$Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.| 
Posicor$DB01388$brand$ASTEMIZOLE$DB00637$true$mechanism$drug$Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. | 
Posicor$DB01388$brand$Cisapride$DB00604$true$mechanism$drug$Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. | 
PRALIDOXIME$DB00733$drug$Atropine$DB00572$true$effect$drug$When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.| 
PRAZOSIN$DB00457$drug$ProAmatine$DB00211$true$effect$brand$ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. | 
Prinivil$DB00722$brand$Spironolactone$DB00421$true$effect$drug$Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.| 
Prinivil$DB00722$brand$TRIAMTERENE$DB00384$true$effect$drug$Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.| 
PROBENECID$DB01032$drug$ACYCLOVIR$DB00787$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.| 
PROBENECID$DB01032$drug$Alimta$DB00642$true$mechanism$brand$Concomitant administration of substances that are also tubularly secreted (e.g., probenecid) could potentially result in delayed clearance of ALIMTA. | 
PROBENECID$DB01032$drug$AMINOSALICYLIC ACID$DB00233$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$drug$AMPICILLIN$DB00415$true$mechanism$drug$Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.| 
PROBENECID$DB01032$drug$Bumetanide$DB00887$true$advise$drug$- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.| This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.| Thus, probenecid should not be administered concurrently with bumetanide.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$drug$Bumetanide$DB00887$true$effect$drug$- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.| This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.| Thus, probenecid should not be administered concurrently with bumetanide.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$drug$Bumetanide$DB00887$true$mechanism$drug$- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.| This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.| Thus, probenecid should not be administered concurrently with bumetanide.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$drug$CEFDINIR$DB00535$true$mechanism$drug$Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.| 
PROBENECID$DB01032$drug$Cefditoren Pivoxil$DB01066$true$mechanism$drug$Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.| 
PROBENECID$DB01032$drug$CIPROFLOXACIN$DB00537$true$mechanism$drug$Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.| 
PROBENECID$DB01032$drug$CLOFIBRATE$DB00636$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$drug$CLOXACILLIN$DB01147$true$mechanism$drug$This might be explained by a blockade by probenecid of the elimination of cloxacillin by the liver.| 
PROBENECID$DB01032$drug$ERTAPENEM$DB00303$true$advise$drug$When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.| Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.| 
PROBENECID$DB01032$drug$ERTAPENEM$DB00303$true$mechanism$drug$When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.| Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.| 
PROBENECID$DB01032$drug$FAMOTIDINE$DB00927$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$drug$Meropenem$DB00760$true$advise$drug$Therefore, the coadministration of probenecid with meropenem is not recommended. | Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. | 
PROBENECID$DB01032$drug$Meropenem$DB00760$true$mechanism$drug$Therefore, the coadministration of probenecid with meropenem is not recommended. | Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. | 
PROBENECID$DB01032$drug$NAPROXEN$DB00788$true$mechanism$drug$Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.| 
PROBENECID$DB01032$drug$NORFLOXACIN$DB01059$true$mechanism$drug$Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.| 
PROBENECID$DB01032$drug$PAH$DB00345$true$effect$drug$Probenecid depresses tubular secretion of certain weak acids such as PAH.| Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.| 
PROBENECID$DB01032$drug$PAH$DB00345$true$mechanism$drug$Probenecid depresses tubular secretion of certain weak acids such as PAH.| Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.| 
PROBENECID$DB01032$drug$PENCICLOVIR$DB00299$true$mechanism$drug$Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.| 
PROBENECID$DB01032$drug$Pipracil$DB00319$true$mechanism$brand$Probenecid: The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.| 
PROBENECID$DB01032$drug$ZALCITABINE$DB00943$true$mechanism$drug$Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.| 
PROBENECID$DB01032$drug$ZIDOVUDINE$DB00495$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROCHLORPERAZINE$DB00433$drug$Camptosar$DB00762$true$effect$brand$The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).| 
Proleukin$DB00041$brand$Dacarbazine$DB00851$true$effect$drug$Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.| 
Proleukin$DB00041$brand$Tamoxifen$DB00675$true$effect$drug$Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.| 
PROPANTHELINE$DB00782$drug$DIGOXIN$DB00390$true$mechanism$drug$Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.| 
PSEUDOEPHEDRINE$DB00852$drug$ProAmatine$DB00211$true$effect$brand$The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | 
Purinethol$DB01033$brand$Tabloid$DB00352$true$effect$brand$There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. | 
PYRIDOXINE$DB00165$drug$Hexalen$DB00488$true$advise$brand$however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1| 
QUININE$DB00468$drug$PRAMIPEXOLE$DB00413$true$mechanism$drug$Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | 
QUININE$DB00468$drug$Tikosyn$DB00204$true$advise$brand$Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| 
Remeron$DB00370$brand$Alcohol$DB00898$true$effect$drug$However, the impairment of cognitive and motor skills produced by REMERON    were shown to be additive with those produced by alcohol. | 
Remeron$DB00370$brand$DIAZEPAM$DB00829$true$effect$drug$However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam. | 
RESERPINE$DB00206$drug$Zebeta$DB00612$true$effect$brand$Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.| 
RETINOL$DB00162$group$ACITRETIN$DB00459$true$advise$drug$Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.| 
RIBAVIRIN$DB00811$drug$STAVUDINE$DB00649$true$effect$drug$Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.| 
RIBAVIRIN$DB00811$drug$ZIDOVUDINE$DB00495$true$effect$drug$Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.| 
RIFABUTIN$DB00615$drug$Crixivan$DB00224$true$advise$brand$Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.| 
RIFABUTIN$DB00615$drug$EFAVIRENZ$DB00625$true$mechanism$drug$Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.| 
RIFABUTIN$DB00615$drug$FLUCONAZOLE$DB00196$true$advise$drug$Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored. | 
RIFABUTIN$DB00615$drug$Viracept$DB00220$true$advise$brand$It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.| Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.| 
RIFABUTIN$DB00615$drug$Viracept$DB00220$true$mechanism$brand$It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.| Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.| 
Rifampin$DB01045$drug$AMPRENAVIR$DB00701$true$mechanism$drug$Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. | Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. | 
Rifampin$DB01045$drug$BEXAROTENE$DB00307$true$mechanism$drug$Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| 
Rifampin$DB01045$drug$Cancidas$DB00520$true$advise$brand$Patients on rifampin should receive 70 mg of CANCIDAS daily.| 
Rifampin$DB01045$drug$CLOZAPINE$DB00363$true$mechanism$drug$Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.| 
Rifampin$DB01045$drug$Diflucan$DB00196$true$mechanism$brand$Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN. | 
Rifampin$DB01045$drug$DIGOXIN$DB00390$true$mechanism$drug$Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.| 
Rifampin$DB01045$drug$EFAVIRENZ$DB00625$true$mechanism$drug$Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.| 
Rifampin$DB01045$drug$Gleevec$DB00619$true$mechanism$brand$Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).| 
Rifampin$DB01045$drug$HALOPERIDOL$DB00502$true$advise$drug$Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.| In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.| 
Rifampin$DB01045$drug$HALOPERIDOL$DB00502$true$mechanism$drug$Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.| In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.| 
Rifampin$DB01045$drug$Ketoconazole$DB01026$true$mechanism$drug$Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.| 
Rifampin$DB01045$drug$METHYLPREDNISOLONE$DB00959$true$advise$drug$Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | 
Rifampin$DB01045$drug$METHYLPREDNISOLONE$DB00959$true$mechanism$drug$Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | 
Rifampin$DB01045$drug$Mexitil$DB00379$true$mechanism$brand$When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. | 
Rifampin$DB01045$drug$MIDAZOLAM$DB00683$true$mechanism$drug$Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. | 
Rifampin$DB01045$drug$MONTELUKAST$DB00471$true$advise$drug$It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.| 
Rifampin$DB01045$drug$NORETHINDRONE$DB00717$true$mechanism$drug$Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.| 
Rifampin$DB01045$drug$Viracept$DB00220$true$mechanism$brand$Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.| 
Rifampin$DB01045$drug$ZALEPLON$DB00962$true$mechanism$drug$Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%.| 
Rifampin$DB01045$drug$Zebeta$DB00612$true$mechanism$brand$Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA.| 
Ritalin$DB00422$brand$GUANETHIDINE$DB01170$true$effect$drug$Ritalin may decrease the hypotensive effect of guanethidine. | 
Ritalin$DB00422$brand$IMIPRAMINE$DB00458$true$mechanism$drug$Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | 
Ritalin$DB00422$brand$PHENOBARBITAL$DB01174$true$mechanism$drug$Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | 
Ritalin$DB00422$brand$PHENYLBUTAZONE$DB00812$true$mechanism$drug$Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | 
Ritalin$DB00422$brand$PRIMIDONE$DB00794$true$mechanism$drug$Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | 
RITONAVIR$DB00503$drug$ALMOTRIPTAN$DB00918$true$advise$drug$Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.| 
RITONAVIR$DB00503$drug$Cisapride$DB00604$true$mechanism$drug$Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| 
RITONAVIR$DB00503$drug$MIDAZOLAM$DB00683$true$mechanism$drug$Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. | 
RITONAVIR$DB00503$drug$Sustiva$DB00625$true$advise$brand$A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.| 
RITONAVIR$DB00503$drug$VARDENAFIL$DB00862$true$mechanism$drug$Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.| Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.| 
RITONAVIR$DB00503$drug$Viracept$DB00220$true$mechanism$brand$Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.| 
Robinul$DB00986$brand$POTASSIUM CHLORIDE$DB00761$true$mechanism$drug$Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.| 
Ropivacaine$DB00296$drug$FLUVOXAMINE$DB00176$true$mechanism$drug$In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. | 
Roxithromycin$DB00778$drug$ASTEMIZOLE$DB00637$true$advise$drug$Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. | 
Sanctura$DB00209$brand$DIGOXIN$DB00390$true$mechanism$drug$Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | 
Sanctura$DB00209$brand$METFORMIN$DB00331$true$mechanism$drug$Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | 
Sanctura$DB00209$brand$PANCURONIUM$DB01337$true$mechanism$drug$Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | 
Sanctura$DB00209$brand$VANCOMYCIN$DB00512$true$mechanism$drug$Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | 
SCOPOLAMINE$DB00747$drug$Alcohol$DB00898$true$advise$drug$Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. | 
Sensipar$DB01012$brand$Ketoconazole$DB01026$true$advise$drug$Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;| 
SERTRALINE$DB01104$drug$SUMATRIPTAN$DB00669$true$effect$drug$Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | 
SERTRALINE$DB08567$drug$SUMATRIPTAN$DB00669$true$effect$drug$Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | 
Skelaxin$DB00660$brand$Alcohol$DB00898$true$effect$drug$SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.| 
Sonata$DB00962$brand$IMIPRAMINE$DB00458$true$effect$drug$Imipramine: Coadministration of single doses of Sonata 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.| 
Spironolactone$DB00421$drug$DIGOXIN$DB00390$true$mechanism$drug$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| 
Sprycel$DB01254$brand$ATAZANAVIR$DB01072$true$mechanism$drug$Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| 
Sprycel$DB01254$brand$Ketoconazole$DB01026$true$mechanism$drug$Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| 
Sprycel$DB01254$brand$NEFAZODONE$DB01149$true$mechanism$drug$Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| 
Sprycel$DB01254$brand$NELFINAVIR$DB00220$true$mechanism$drug$Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| 
Sprycel$DB01254$brand$RITONAVIR$DB00503$true$mechanism$drug$Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| 
Stadol NS$DB00611$brand$SUMATRIPTAN$DB00669$true$effect$drug$When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.| However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.| These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.| 
Stadol NS$DB00611$brand$SUMATRIPTAN$DB00669$true$mechanism$drug$When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.| However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.| These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.| 
Starlix$DB00731$brand$TOLBUTAMIDE$DB01124$true$mechanism$drug$Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide.| 
STAVUDINE$DB00649$drug$RIBAVIRIN$DB00811$true$effect$drug$In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. | 
Strattera$DB00289$brand$Albuterol$DB01001$true$advise$drug$Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.| 
Strattera$DB00289$brand$PAROXETINE$DB00715$true$advise$drug$Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.| 
SUCCINYLCHOLINE$DB00202$drug$Brevibloc$DB00187$true$effect$brand$The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.| 
SUCCINYLCHOLINE$DB00202$drug$Coly-Mycin M$DB01111$true$effect$brand$Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.| 
SUCCINYLCHOLINE$DB00202$drug$Mivacron$DB01226$true$advise$brand$Evidence of spontaneous recovery from succinylcholine should be observed before the administration of MIVACRON. | 
SUCCINYLCHOLINE$DB00202$drug$Nimbex$DB00565$true$effect$brand$Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.| 
SULFAMETHIZOLE$DB00576$drug$TOLBUTAMIDE$DB01124$true$effect$drug$Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. | 
SULFAPYRIDINE$DB00891$drug$Tylenol$DB00316$true$int$brand$Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or| 
SULFASALAZINE$DB00795$drug$DIGOXIN$DB00390$true$mechanism$drug$Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.| 
SULFASALAZINE$DB00795$drug$Enbrel$DB00005$true$effect$brand$Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.| 
SULFOXONE$DB01145$drug$TOLBUTAMIDE$DB01124$true$effect$drug$Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. | 
SUMATRIPTAN$DB00669$drug$D.H.E. 45$DB00320$true$advise$brand$Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.| Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..| 
SUMATRIPTAN$DB00669$drug$D.H.E. 45$DB00320$true$effect$brand$Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.| Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..| 
SUMATRIPTAN$DB00669$drug$ESCITALOPRAM$DB01175$true$advise$drug$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUMATRIPTAN$DB00669$drug$FLUVOXAMINE$DB00176$true$advise$drug$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUMATRIPTAN$DB00669$drug$PAROXETINE$DB00715$true$advise$drug$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUMATRIPTAN$DB00669$drug$SERTRALINE$DB01104$true$advise$drug$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUMATRIPTAN$DB00669$drug$SERTRALINE$DB08567$true$advise$drug$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
Sustiva$DB00625$brand$Ketoconazole$DB01026$true$mechanism$drug$SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.| 
Sustiva$DB00625$brand$RITONAVIR$DB00503$true$advise$drug$Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir.| 
Sutent$DB01268$brand$ATAZANAVIR$DB01072$true$mechanism$drug$Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | 
Sutent$DB01268$brand$DEXAMETHASONE$DB01234$true$mechanism$drug$Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | 
Sutent$DB01268$brand$Ketoconazole$DB01026$true$mechanism$drug$Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | 
Sutent$DB01268$brand$NEFAZODONE$DB01149$true$mechanism$drug$Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | 
Sutent$DB01268$brand$NELFINAVIR$DB00220$true$mechanism$drug$Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | 
Sutent$DB01268$brand$PHENOBARBITAL$DB01174$true$mechanism$drug$Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | 
Sutent$DB01268$brand$RIFABUTIN$DB00615$true$mechanism$drug$Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | 
Sutent$DB01268$brand$Rifampin$DB01045$true$mechanism$drug$Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | 
Sutent$DB01268$brand$RITONAVIR$DB00503$true$mechanism$drug$Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | 
Symlin$DB01278$brand$Atropine$DB00572$true$advise$drug$Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). | 
Tagamet$DB00501$brand$CHLORDIAZEPOXIDE$DB00475$true$mechanism$drug$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| 
Tagamet$DB00501$brand$DIAZEPAM$DB00829$true$mechanism$drug$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| 
Tagamet$DB00501$brand$METRONIDAZOLE$DB00916$true$mechanism$drug$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| 
Tagamet$DB00501$brand$Theo-Dur$DB00277$true$mechanism$brand$However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.| 
Tambocor$DB01195$brand$DIGOXIN$DB00390$true$mechanism$drug$During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.| 
Tamoxifen$DB00675$drug$ANASTROZOLE$DB01217$true$advise$drug$Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).| 
Tamoxifen$DB00675$drug$PAROXETINE$DB00715$true$advise$drug$It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. | 
Tarceva$DB00530$brand$ATAZANAVIR$DB01072$true$advise$drug$Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| 
Tarceva$DB00530$brand$Ketoconazole$DB01026$true$advise$drug$Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| 
Tarceva$DB00530$brand$NEFAZODONE$DB01149$true$advise$drug$Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| 
Tarceva$DB00530$brand$NELFINAVIR$DB00220$true$advise$drug$Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| 
Tarceva$DB00530$brand$RITONAVIR$DB00503$true$advise$drug$Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| 
Tarceva$DB00530$brand$Tao$DB01361$true$advise$drug$Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| 
Tarceva$DB00530$brand$TROLEANDOMYCIN$DB01361$true$advise$drug$Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| 
Tarceva$DB00530$brand$VORICONAZOLE$DB00582$true$advise$drug$Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| 
Targretin$DB00307$brand$GEMFIBROZIL$DB01241$true$mechanism$drug$Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.| 
TERBINAFINE$DB00857$drug$Rifampin$DB01045$true$mechanism$drug$Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. | 
TIAGABINE$DB00906$drug$PHENOBARBITAL$DB01174$true$mechanism$drug$Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.| 
TIAGABINE$DB00906$drug$PRIMIDONE$DB00794$true$mechanism$drug$Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.| 
TIAGABINE$DB00906$drug$Valproate$DB00313$true$mechanism$drug$Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.| 
TICAGRELOR$DB08816$drug$Aspirin$DB00945$true$effect$brand$The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). | 
Tikosyn$DB00204$brand$Verapamil$DB00661$true$mechanism$drug$Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.| 
Tobi$DB00684$brand$MANNITOL$DB00742$true$advise$drug$TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.| 
Tobi$DB00684$brand$Pulmozyme$DB00003$true$effect$brand$In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. | 
TOLBUTAMIDE$DB01124$drug$APREPITANT$DB00673$true$mechanism$drug$Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.| 
TOLBUTAMIDE$DB01124$drug$Atromid-S$DB00636$true$effect$brand$The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.| 
Toradol$DB00465$brand$ALPRAZOLAM$DB00404$true$effect$drug$Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).| 
Toradol$DB00465$brand$PROBENECID$DB01032$true$advise$drug$Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.| Therefore, concomitant use of TORADOL and probenecid is contraindicated.| 
Toradol$DB00465$brand$PROBENECID$DB01032$true$mechanism$drug$Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.| Therefore, concomitant use of TORADOL and probenecid is contraindicated.| 
Toradol$DB00465$brand$THIOTHIXENE$DB01623$true$effect$drug$Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).| 
Trecator$DB00609$brand$ISONIAZID$DB00951$true$mechanism$drug$Trecator has been found to temporarily raise serum concentrations of isoniazid.| 
Triacetyloleandomycin$DB01361$drug$ERGOTAMINE$DB00696$true$mechanism$drug$The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.| 
TRIAMTERENE$DB00384$drug$DOFETILIDE$DB00204$true$advise$drug$In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| 
TRIAMTERENE$DB00384$drug$Indocin$DB00328$true$effect$brand$It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.| 
TRIAMTERENE$DB00384$drug$PRAMIPEXOLE$DB00413$true$mechanism$drug$Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | 
TRIAZOLAM$DB00897$drug$APREPITANT$DB00673$true$advise$drug$The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| 
TRIAZOLAM$DB00897$drug$FLUVOXAMINE$DB00176$true$mechanism$drug$Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| 
TRIAZOLAM$DB00897$drug$TIAGABINE$DB00906$true$advise$drug$Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.| 
Trileptal$DB00776$brand$Felodipine$DB01023$true$mechanism$drug$Calcium Antagonists: After repeated co-administration of Trileptal, the AUC of felodipine was lowered by 28% [90% CI: 20-33].| 
TRILOSTANE$DB01108$drug$Mitotane$DB00648$true$int$drug$Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).| 
TRIMETREXATE$DB01157$drug$FLUCONAZOLE$DB00196$true$effect$drug$Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | 
TRIMETREXATE$DB01157$drug$Ketoconazole$DB01026$true$effect$drug$Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | 
TRIMETREXATE$DB01157$drug$RIFABUTIN$DB00615$true$effect$drug$Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | 
TRIMETREXATE$DB01157$drug$Rifampin$DB01045$true$effect$drug$Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | 
TRIPELENNAMINE$DB00792$drug$Pentazocine$DB00652$true$effect$drug$Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine. | 
TRIPROLIDINE$DB00427$drug$Alcohol$DB00898$true$effect$drug$Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. | 
Trisenox$DB01169$brand$AMPHOTERICIN B$DB00681$true$advise$drug$Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).| 
TROLEANDOMYCIN$DB01361$drug$Cisapride$DB00604$true$mechanism$drug$Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| 
TROLEANDOMYCIN$DB01361$drug$METHYLPREDNISOLONE$DB00959$true$mechanism$drug$Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. | 
TUBOCURARINE$DB01199$drug$Coly-Mycin M$DB01111$true$effect$brand$Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.| 
VALDECOXIB$DB00580$drug$Dextromethorphan$DB00514$true$mechanism$drug$Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.| 
VALDECOXIB$DB00580$drug$DIAZEPAM$DB00829$true$effect$drug$Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.| 
VALDECOXIB$DB00580$drug$FLUCONAZOLE$DB00196$true$mechanism$drug$Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.| Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.| 
VALDECOXIB$DB00580$drug$Ketoconazole$DB01026$true$mechanism$drug$Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.| Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.| 
Valproate$DB00313$drug$ISONIAZID$DB00951$true$mechanism$drug$Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.| 
Valproate$DB00313$drug$TIAGABINE$DB00906$true$mechanism$drug$Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.| 
VALPROIC ACID$DB00313$drug$PHENOBARBITAL$DB01174$true$effect$drug$Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. | 
VALPROIC ACID$DB00313$drug$PHENOBARBITAL$DB01174$true$mechanism$drug$Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. | 
VALPROIC ACID$DB00313$drug$TEMOZOLOMIDE$DB00853$true$mechanism$drug$Administration of valproic acid decreases oral clearance of temozolomide by about 5%. | 
VARDENAFIL$DB00862$drug$Ketoconazole$DB01026$true$advise$drug$Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.| A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.| 
VARDENAFIL$DB00862$drug$RITONAVIR$DB00503$true$advise$drug$Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.| The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.| Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.| 
VARDENAFIL$DB00862$drug$RITONAVIR$DB00503$true$mechanism$drug$Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.| The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.| Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.| 
VARDENAFIL$DB00862$drug$TAMSULOSIN$DB00706$true$effect$drug$In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.| Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.| 
Verapamil$DB00661$drug$Adenocard$DB00640$true$effect$brand$Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.| 
Verapamil$DB00661$drug$DIGOXIN$DB00390$true$mechanism$drug$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| 
Verapamil$DB00661$drug$DOFETILIDE$DB00204$true$effect$drug$In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.| 
Verapamil$DB00661$drug$MIDAZOLAM$DB00683$true$mechanism$drug$Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | 
Verapamil$DB00661$drug$PRAMIPEXOLE$DB00413$true$mechanism$drug$Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | 
Verapamil$DB00661$drug$Tambocor$DB01195$true$advise$brand$Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.| 
Vesicare$DB01591$brand$Ketoconazole$DB01026$true$advise$drug$Do not exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors. | 
Videx$DB00900$brand$CIPROFLOXACIN$DB00537$true$advise$drug$Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| 
Videx$DB00900$brand$Factive$DB01155$true$advise$brand$Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| 
Videx$DB00900$brand$GANCICLOVIR$DB01004$true$mechanism$drug$Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).| A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).| 
Videx$DB00900$brand$NORFLOXACIN$DB01059$true$advise$drug$Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.| 
Vioxx$DB00533$brand$Rifampin$DB01045$true$mechanism$drug$Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.| 
Viracept$DB00220$brand$AMIODARONE$DB01118$true$advise$drug$Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| 
Viracept$DB00220$brand$ASTEMIZOLE$DB00637$true$advise$drug$Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| Because a similar interaction is likely, VIRACEPT should also not be administered concurrently with astemizole.| 
Viracept$DB00220$brand$Cisapride$DB00604$true$advise$drug$Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| 
Viracept$DB00220$brand$MIDAZOLAM$DB00683$true$advise$drug$Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| 
Viracept$DB00220$brand$RIFABUTIN$DB00615$true$advise$drug$Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin| 
Viracept$DB00220$brand$Rifampin$DB01045$true$advise$drug$VIRACEPT and rifampin should not be coadministered.| Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| 
Viracept$DB00220$brand$TRIAZOLAM$DB00897$true$advise$drug$Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| 
Vistide$DB00369$brand$Amikacin$DB00479$true$advise$drug$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| 
Vistide$DB00369$brand$AMPHOTERICIN B$DB00681$true$advise$drug$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| 
Vistide$DB00369$brand$FOSCARNET$DB00529$true$advise$drug$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| 
Vistide$DB00369$brand$PENTAMIDINE$DB00738$true$advise$drug$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| 
Vistide$DB00369$brand$TOBRAMYCIN$DB00684$true$advise$drug$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| 
Vistide$DB00369$brand$VANCOMYCIN$DB00512$true$advise$drug$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| 
Vitamin B1$DB00152$drug$STAVUDINE$DB00649$true$int$drug$Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants| 
Vitamin B12$DB00115$drug$AMINOSALICYLIC ACID$DB00233$true$advise$drug$Therefore you may need to take a vitamin B12 supplement while taking aminosalicylic acid.| 
Welchol$DB00930$brand$Calan SR$DB00661$true$mechanism$brand$WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.| 
Welchol$DB00930$brand$Verapamil$DB00661$true$mechanism$drug$WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.| 
Wellbutrin$DB01156$brand$Cyclophosphamide$DB00531$true$int$drug$Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).| 
ZAFIRLUKAST$DB00549$drug$Tikosyn$DB00204$true$advise$brand$Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| 
ZALCITABINE$DB00943$drug$ALUMINUM$DB01370$true$advise$drug$The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.| 
ZALCITABINE$DB00943$drug$Lamivudine$DB00709$true$advise$drug$Concomitant use of zalcitabine and lamivudine is not recommended.| Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);| These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.| 
ZALCITABINE$DB00943$drug$Lamivudine$DB00709$true$effect$drug$Concomitant use of zalcitabine and lamivudine is not recommended.| Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);| These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.| 
ZALCITABINE$DB00943$drug$METOCLOPRAMIDE$DB01233$true$mechanism$drug$Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.| 
ZALCITABINE$DB00943$drug$ZDV$DB00495$true$effect$drug$Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).| 
Zavesca$DB00419$brand$Cerezyme$DB00053$true$mechanism$brand$While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. | 
Zebeta$DB00612$brand$CLONIDINE$DB00575$true$advise$drug$In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.| 
Zebeta$DB00612$brand$Verapamil$DB00661$true$advise$drug$ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.| 
Zemplar$DB00910$brand$Ketoconazole$DB01026$true$advise$drug$Dose adjustment of Zemplar Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole. | 
Zemuron$DB00728$brand$SUCCINYLCHOLINE$DB00202$true$advise$drug$If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. | 
ZIDOVUDINE$DB00495$drug$PROBENECID$DB01032$true$advise$drug$Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.| 
ZIDOVUDINE$DB00495$drug$STAVUDINE$DB00649$true$effect$drug$Zidovudine competitively inhibits the intracellular phosphorylation of stavudine. | 
ZIDOVUDINE$DB00495$drug$Viracept$DB00220$true$advise$brand$A dose adjustment is not needed when zidovudine is administered with VIRACEPT.| 
ZIDOVUDINE$DB00495$drug$Zerit$DB00649$true$advise$brand$Therefore, use of zidovudine in combination with ZERIT should be avoided. | 
Zolinza$DB02546$brand$VALPROIC ACID$DB00313$true$effect$drug$Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). | 
Zopiclone$DB01198$drug$Romazicon$DB01205$true$effect$brand$The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as zopiclone, triazolopyridazines and others, are also blocked by ROMAZICON.| 
